NCT00071708Approved For MarketingNot Applicable
Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Approved For Marketing
- Sponsor
- Eli Lilly and Company
- Locations
- 1
Study Overview
Brief Summary
The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.
Study Design
- Study Type
- Expanded Access
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Male and Female outpatients at least 18 years of age who have previously participated in a Lilly sponsored neuroscience duloxetine clinical trial
- •All females must have a negative urine pregnancy test at visit
- •Females of childbearing potential must agree to utilize medically acceptable and reliable means of birth control.
- •Must sign the informed consent document
Exclusion Criteria
- •Have received treatment within the last 30 days with a drug except for duloxetine that has not received regulatory approval for any indication at the time of study entry
- •In the opinion of the investigator, patient judged to be at serious suicidal risk.
- •Serious or unstable hepatic or renal function or unstable narrow angle glaucoma.
- •Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to visit 1 or potential to use a MAOI during the study or within 5 days of discontinuation of study drug.
- •Any patient who previously experienced a serious adverse event while taking duloxetine unless approved by the Lilly Physician
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 4
An Open Label Trial of Duloxetine in the Treatment of Irritable Bowel Syndrome and Comorbid Generalized Anxiety DisorderIrritable Bowel SyndromeGeneralized Anxiety DisorderNCT00961298West Penn Allegheny Health System17
Completed
Phase 3
Open-Label Treatment With Duloxetine Hydrochloride Once-Daily Dosing for Evaluation of Stabilization Dose in Patients With Major DepressionMajor Depressive DisorderNCT00042562Eli Lilly and Company
Completed
Phase 3
Subject Information and Consent Form F1J-US-HMCB Duloxetine Once-Daily Dosing Versus Placebo in Patients With Major Depression and PainPainDepressionNCT00036335Eli Lilly and Company286
Completed
Phase 3
A Study of Duloxetine in FibromyalgiaFibromyalgiaNCT01552057Eli Lilly and Company393
Completed
Phase 3
An Extension Study of Duloxetine in Osteoarthritis and Knee Pain (Extension of F1J-JE-HMGX, NCT02248480)Osteoarthritis of the KneeNCT02335346Eli Lilly and Company93